Full Press Release Details
Appoints Corinne Nevinny to Board of Directors
ACTON, Mass.--(BUSINESS WIRE)--January 28, 2019--Insulet Corporation
(NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless
insulin pump technology with its Omnipod Insulin
Management System (Omnipod System), today announced that Corinne Nevinny
has been appointed to the Company's Board of Directors, effective
immediately. Ms. Nevinny replaces James Mullen, who is stepping down
from Insulet's Board to focus on his family's philanthropic foundation
and other business ventures.
Ms. Nevinny is the General Partner of LMNVC, a seed venture fund making
early-round investments in start-up companies that have products or
services that improve quality of life, including health and wellness
oriented businesses. From 2003 to 2010, she served in a variety of roles
at Edwards Lifesciences Corporation, including General Manager - Cardiac
Surgery Systems, President of Global Operations, and Chief Financial
Officer and Treasurer. In these roles, Ms. Nevinny was at various times
responsible for global sales, manufacturing, quality and supply chain
operations, as well as oversight of core operating units including
finance, IT, internal audit and risk management.
"On behalf of the Board, I am very pleased to welcome Corinne to
Insulet," said Timothy Scannell, Chairman of Insulet's Board of
Directors. "Corinne's talents are an excellent complement to our
existing Board skill set. She brings strategic acumen and demonstrated,
successful industry experience. We are delighted that a proven leader
like Corinne has joined our Board and look forward to her contributions
as Insulet continues to accelerate growth and deliver value to our
Mr. Scannell continued, "Insulet has been well served by Jim's
contributions and on behalf of the entire Board and management team, I
thank him for his service to the Company and wish him all the best in
his future endeavors."
About Corinne Nevinny:
Corinne Nevinny has been the General Partner of LMNVC since August 2010.
LMNVC is a seed venture fund making early-round investments in women
owned or run start-up companies that have products or services that
improve quality of life, including clean, green, health, wellness,
fitness and education oriented businesses. From 2003 to 2010, she held
multiple positions at Edwards Lifesciences Corporation, including
General Manager - Cardiac Surgery Systems, President of Global
Operations, and Chief Financial Officer and Treasurer. Prior to joining
Edwards, Ms. Nevinny held various finance and investment banking
positions. Ms. Nevinny is a member of the Board of Trustees and
Executive Committee of the United States Olympic and Paralympic
Foundation and serves on the Board of Directors of Restorsea LLC. She
previously served on the Board of privately-held nVision, as well as
public company Boards, including Edwards Life Sciences Corporation
(NYSE: EW), Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR), Neurocrine
Biosciences (NASDAQ: NBIX), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX),
and SangStat Medical Corp. (NASDAQ: SANG) and chaired the Audit
Committees for Avanir, Neurocrine and Onyx. Ms. Nevinny holds a Bachelor
of Science in Industrial Engineering from Stanford University and a
Master of Business Administration from Harvard Business School.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is
an innovative medical device company dedicated to making the lives of
people with diabetes and other conditions easier through the use of its
Omnipod product platform. The Omnipod Insulin Management System provides
a unique alternative to traditional insulin delivery methods. With its
simple, wearable design, the disposable Pod provides up to three days of
non-stop insulin delivery, without the need to see or handle a needle.
Insulet also leverages the unique design of its Pod by tailoring its
Omnipod technology platform for the delivery of non-insulin subcutaneous
drugs across multiple therapeutic areas. Founded in 2000, Insulet has
more than 150,000 users across the globe who rely on its Omnipod Insulin
Management System to bring simplicity and freedom to their lives.
For more information, please visit: www.insulet.com and www.myomnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements concerning
Insulet's expectations, anticipations, intentions, beliefs or strategies
regarding the future. These forward-looking statements are based on its
current expectations and beliefs concerning future developments and
their potential effects on Insulet. There can be no assurance that
future developments affecting Insulet will be those that it has
anticipated. These forward-looking statements involve a number of risks,
uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties described
in its Annual Report on Form 10-K, which was filed with the Securities
and Exchange Commission on February 22, 2018 in the section entitled
"Risk Factors," and in its other filings from time to time with the
Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should any of its assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. Insulet undertakes no
obligation to publicly update or revise any forward-looking statements.
2019 Insulet Corporation. Omnipod and the Omnipod logo are trademarks
Investor Relations and Media Contact:
R. Gordon, 978-600-7717
Vice President, Investor Relations and
Corporate Communications